[95]
The Federal Court of Appeal came to a similar conclusion in a case involving the drug clopidogrel (Plavix). The patent at issue claimed an enantiomer. Although the racemate had been previously disclosed, the prior art patent "did not specifically lead to the claimed invention. The processes disclosed only resulted in a racemate ..." (
Sanofi-Synthelabo Canada Inc. et al. v. Apotex Inc. et al.
(2005), 271 F.T.R. 159; 2005 FC 390, at para. 28 (
Sanofi-Synthelabo v. Apotex
), affd. (2006), 358 N.R. 135; 282 D.L.R.(4th) 179; 2006 FCA 421, SCC heard in April 2008 and currently under reserve)